Division of Pulmonary, Allergy and Critical Care Medicine, Atlanta VA Medical Center, Decatur, GA 30033, USA.
Ther Adv Respir Dis. 2010 Jun;4(3):143-60. doi: 10.1177/1753465809369619.
Pulmonary hypertension (PH) is a progressive disorder of the pulmonary circulation associated with significant morbidity and mortality. The pathobiology of PH involves a complex series of derangements causing endothelial dysfunction, vasoconstriction and abnormal proliferation of pulmonary vascular wall cells that lead to increases in pulmonary vascular resistance and pressure. Recent evidence indicates that the ligand-activated transcription factor, peroxisome proliferator-activated receptor gamma (PPARgamma) can have a favorable impact on a variety of pathways involved in the pathogenesis of PH. This review summarizes PPARgamma biology and the emerging evidence that therapies designed to activate this receptor may provide novel approaches to the treatment of PH. Mediators of PH that are regulated by PPARgamma are reviewed to provide insights into potential mechanisms underlying therapeutic effects of PPARgamma ligands in PH.
肺动脉高压（PH）是一种与显著发病率和死亡率相关的肺循环进行性疾病。PH 的病理生物学涉及一系列复杂的紊乱，导致内皮功能障碍、血管收缩和肺血管壁细胞的异常增殖，从而导致肺血管阻力和压力增加。最近的证据表明，配体激活的转录因子过氧化物酶体增殖物激活受体γ（PPARγ）可以对 PH 发病机制中涉及的多种途径产生有利影响。本综述总结了 PPARγ 的生物学特性以及新兴证据，表明旨在激活该受体的治疗方法可能为 PH 的治疗提供新方法。综述了受 PPARγ调节的 PH 介质，以深入了解 PH 中 PPARγ 配体治疗效果的潜在机制。
